Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition Sciences, Department of Nutrition, Maragheh University of Medical Sciences, Maragheh, Iran.
BMC Endocr Disord. 2024 Oct 8;24(1):210. doi: 10.1186/s12902-024-01738-7.
Abnormalities in biochemical parameters and changes in eating habits are considered complications of obesity. Oleoylethanolamide (OEA), an endocannabinoid-like compound, has been shown to have protective effects on many metabolic disorders. Given this evidence, the present study aimed to assess the effects of OEA on lipid profile parameters, fasting blood sugar (FBS), and dietary habits in healthy obese people.
In this randomized, double-blind, placebo-controlled clinical trial, which was carried out in 2016 in Tabriz, Iran, 60 obese people were enrolled in the study based on inclusion criteria. The intervention group consumed 125 mg of OEA capsules, and the placebo group received the same amount of starch twice for 8 weeks. Blood samples (5 mL) were taken at baseline and the end of the study in a fasting state. Serum concentrations of FBS, triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC) were measured by enzymatic methods using commercial kits. The low-density lipoprotein cholesterol (LDL-C) concentration was obtained using the Friede-Wald formula. To assess dietary habits, a food frequency questionnaire (147 items) was used at baseline and the end of the study. A value less than < 0.05 was considered to indicate statistical significance.
The TG concentration decreased significantly in the intervention group (mean (SD): 166.29 (70.01) mg/dL to 142.22 (48.05) mg/dL, p = 0.047). Changes in the placebo group were not significant (p > 0.05). After adjusting for baseline values and demographic characteristics, the difference in TG between groups remained significant (p = 0.044). Changes in other biochemical parameters were not significant. There was no significant difference between or within groups in terms of food groups.
OEA, as a complementary agent, plays a protective role in TG regulation. However, future studies with longer durations are needed to explore the impact of OEA on regulating dietary habits and to identify the mechanisms related to metabolic abnormalities in obese people.
The study was registered in the Iranian Registry of Clinical Trials (IRCT) center as IRCT201607132017N30 with URL. www.IRCT.IR in date 03/10/2016.
生化参数异常和饮食习惯改变被认为是肥胖的并发症。奥利诺酰胺(OEA),一种类似内源性大麻素的化合物,已被证明对许多代谢紊乱具有保护作用。鉴于这一证据,本研究旨在评估 OEA 对健康肥胖人群的血脂参数、空腹血糖(FBS)和饮食习惯的影响。
本研究为 2016 年在伊朗大不里士进行的一项随机、双盲、安慰剂对照临床试验,根据纳入标准,共纳入 60 名肥胖者。干预组每天服用 125mg 的 OEA 胶囊,而安慰剂组在 8 周内每天服用两次等量的淀粉。在禁食状态下,采集基线和研究结束时的 5ml 血样。使用商业试剂盒,通过酶法测量血清中 FBS、三酰甘油(TGs)、高密度脂蛋白胆固醇(HDL-C)和总胆固醇(TC)的浓度。使用 Friede-Wald 公式获得低密度脂蛋白胆固醇(LDL-C)浓度。为了评估饮食习惯,在基线和研究结束时使用了一份包含 147 个项目的食物频率问卷。小于<0.05 被认为具有统计学意义。
干预组 TG 浓度显著下降(均值(SD):166.29(70.01)mg/dL 降至 142.22(48.05)mg/dL,p=0.047)。安慰剂组的变化不显著(p>0.05)。调整基线值和人口统计学特征后,两组间 TG 的差异仍有统计学意义(p=0.044)。其他生化参数的变化不显著。组间和组内各食物组均无显著差异。
OEA 作为一种补充剂,在调节 TG 方面发挥保护作用。然而,需要进行更长时间的研究,以探讨 OEA 对调节饮食习惯和识别肥胖人群代谢异常相关机制的影响。
本研究在伊朗临床试验注册中心(IRCT)注册,注册号为 IRCT201607132017N30,网址为 www.IRCT.IR,注册日期为 2016 年 10 月 3 日。